Kalkine has a fully transformed New Avatar.

Switch to Old version
1800-272-662
Kalkine 0
countryflagAU

Imugene Ltd

Healthcare AU IMU

0.425AUD
0.03(6.25%)

Last update at 2025-07-11T06:10:00Z

Day Range

0.390.42
LowHigh

52 Week Range

0.342.75
LowHigh

Fundamentals

  • Previous Close 0.40
  • Market Cap173.09M
  • Volume262978
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-116.81624M
  • Revenue TTM-1.83960M
  • Revenue Per Share TTM-
  • Gross Profit TTM -1.83960M
  • Diluted EPS TTM-0.6

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Income before tax -39.17108M -37.86917M -18.45536M -10.50800M -7.77536M
Minority interest - - - - -
Net income -39.17108M -37.97592M -25.76667M -14.58706M -7.77568M
Selling general administrative 17.77M 12.10M 9.44M 4.29M 3.81M
Selling and marketing expenses 0.51M 0.33M 0.15M 0.28M 0.43M
Gross profit - - - - 4.13M
Reconciled depreciation 0.19M 0.20M 0.10M 0.08M 0.06M
Ebit -51.29082M -37.65758M -18.34433M -10.50297M -7.76893M
Ebitda -51.10050M -37.45422M -18.24013M -10.42047M -7.70567M
Depreciation and amortization 0.19M 0.20M 0.10M 0.08M 0.06M
Non operating income net other - - - - -
Operating income -51.29082M -37.65758M -18.34433M -10.50297M -7.76893M
Other operating expenses 51.29M 50.67M 25.67M 14.88M 12.39M
Interest expense - 0.11M 0.11M 0.00503M 0.00611M
Tax provision 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Interest income 1.88M 0.19M 0.13M 0.30M 0.41M
Net interest income 1.85M 0.07M 0.01M 0.30M 0.41M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -1.84994M 0.11M 7.31M 4.08M 0.00032M
Total revenue - 0.00000M 0.00000M 4.21M 4.54M
Total operating expenses 51.29M 50.67M 25.67M 14.88M 12.39M
Cost of revenue - - - - -
Total other income expense net 10.27M -0.21159M -0.11103M -0.00503M -0.00643M
Discontinued operations - - - - -
Net income from continuing ops -39.17108M -37.86917M -18.45536M -10.50800M -7.77536M
Net income applicable to common shares -37.91489M -37.86917M -18.45536M -10.50800M -7.77536M
Preferred stock and other adjustments - - - - -
Breakdown 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Type yearly yearly yearly yearly yearly
Date 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Total assets 151.40M 195.81M 147.61M 71.81M 65.20M
Intangible assets 34.12M 30.49M 32.69M 34.89M 30.46M
Earning assets - - - - -
Other current assets 7.31M 0.40M 1.11M 0.17M 0.19M
Total liab 33.14M 7.44M 8.90M 6.79M 5.40M
Total stockholder equity 118.25M 188.37M 138.70M 65.02M 59.81M
Deferred long term liab - - - - -
Other current liab 22.42M 1.92M 1.42M 2.85M 1.43M
Common stock 370.31M 314.40M 230.79M 113.11M 92.80M
Capital stock 370.31M 314.40M 230.79M 113.11M 104.89M
Retained earnings -289.83175M -142.69219M -103.52112M -65.65194M -47.31026M
Other liab - 0.99M 0.99M 2.17M 2.49M
Good will - - - - -
Other assets - 0.02M 0.03M 0.02M 0.02M
Cash 93.11M 153.15M 99.89M 29.49M 30.11M
Cash and equivalents - 49.54M 29.00M 21.00M 25.00M
Total current liabilities 29.30M 6.08M 7.42M 4.46M 2.90M
Current deferred revenue - 1.63M 1.30M 0.74M 0.39M
Net debt -91.56061M -152.59719M -99.21429M -29.21600M -30.03742M
Short term debt 0.91M 0.19M 0.18M 0.11M 0.06M
Short long term debt - - - - -
Short long term debt total 1.55M 0.55M 0.67M 0.27M 0.07M
Other stockholder equity - -172.96587M -127.26763M -47.45497M -45.48730M
Property plant equipment - 0.68M 0.86M 0.47M 0.16M
Total current assets 113.03M 164.40M 113.77M 36.32M 34.49M
Long term investments 2.41M 0.22M 0.25M 0.12M 0.08M
Net tangible assets - 159.14M 106.02M 30.12M 29.35M
Short term investments 1.44M - -0.00000M - -
Net receivables 12.62M 10.85M 12.77M 6.66M 4.19M
Long term debt - - - - -
Inventory - - - - -
Accounts payable 5.97M 2.34M 4.51M 0.76M 1.01M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 37.77M 16.66M 11.44M 17.56M 14.32M
Additional paid in capital - - - - -
Common stock total equity - - - - 104.89M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.13M 0.02M 0.03M 0.02M 0.02M
Deferred long term asset charges - - - - -
Non current assets total 38.36M 31.41M 33.84M 35.49M 30.71M
Capital lease obligations - 0.55M 0.67M 0.27M 0.07M
Long term debt total - 0.36M 0.49M 0.17M 0.00840M
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Investments 1.89M -0.13717M -0.03456M -0.03064M -0.02969M
Change to liabilities -1.38542M 2.85M 0.03M -0.99994M 1.89M
Total cashflows from investing activities 1.89M -0.22099M -5.32640M -1.20665M 0.25M
Net borrowings -0.14741M -0.01081M 0.07M -0.05356M -0.04114M
Total cash from financing activities 82.98M 101.34M 17.99M 22.71M 18.77M
Change to operating activities 0.71M -0.94002M 0.02M 0.01M -0.06428M
Net income -37.91489M -37.86917M -18.45536M -10.50800M -7.77568M
Change in cash 53.26M 70.40M -0.61973M 11.06M 11.23M
Begin period cash flow 99.89M 29.49M 30.11M 19.05M 7.82M
End period cash flow 153.15M 99.89M 29.49M 30.11M 19.05M
Total cash from operating activities -31.47096M -30.84814M -13.28001M -10.43777M -7.90949M
Issuance of capital stock 88.17M 108.88M 18.05M 24.57M 20.26M
Depreciation 2.39M 2.41M 1.96M 0.08M 0.06M
Other cashflows from investing activities 1.89M 0.17M 0.16M 0.31M 0.41M
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables 1.09M -6.10750M -2.45527M -0.03357M -2.30664M
Sale purchase of stock -5.04192M -6.15137M -0.12557M -1.80108M -1.44396M
Other cashflows from financing activities -0.14741M -1.38504M 0.06M -0.05859M -0.04725M
Change to netincome 3.64M 8.81M 5.62M 1.01M 0.28M
Capital expenditures 0.00000M 0.28M 5.45M 1.49M 0.14M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 1.09M -6.10750M -2.45527M -0.03357M 1.87M
Stock based compensation 5.64M 4.10M 5.56M 1.27M -
Other non cash items 4.05M 4.61M 3.21M -0.01226M 7.71M
Free cash flow -31.47096M -31.12513M -18.72776M -11.92446M -8.05347M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
IMU
Imugene Ltd		 0.03 6.25% 0.42 - - 56.40 2.59 -15.5112
CSL
CSL Ltd		 -1.49 0.61% 240.92 28.85 32.79 7.69 4.14 5.94 18.43
TLX
Telix Pharmaceuticals Ltd		 -0.38 1.55% 24.09 163.67 47.85 10.52 14.41 10.29 87.11
MSB
Mesoblast Ltd		 0.01 0.61% 1.66 - 454.55 369.57 2.96 67.90 -9.8623
NEU
Neuren Pharmaceuticals Ltd		 -0.04 0.27% 14.57 13.39 35.21 8.48 5.06 7.81 9.49

Reports Covered

Stock Research & News

View All

Profile

Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumours in Australia. Its lead products under development azer-cel, an allogeneic CAR T cell therapy in phase 1 clinical trial targeting relapsed/refractory non-hodgkin lymphoma and b-cell acute lymphoblastic leukemia; CF33 VAXINIA, a combination of genomic sequences from various vaccinia virus strains to generate potent virus in phase 1 clinical trial for mixed advanced solid tumours; and CF33 CD19 chimeric antigen receptor T cells therapies to target solid tumours in phase 1 study. The company also develops CF33 oncolytic virotherapy CHECKvacc in phase 1 clinical trial for triple negative breast cancer; HER-VAXX, a B-cell immunotherapy cancer vaccine completed phase 2 clinical trial to target metastatic and advanced gastric cancer; PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling in phase 2 clinical trial to target non-small cell lung cancer; and NeoPOLEM in phase 2 study for MSI-high colorectal cancer. The company has a research collaboration with NeoImmuneTech to enhance cancer treatments. Imugene Limited is based in Sydney, Australia.

Imugene Ltd

4-6 Bligh Street, Sydney, NSW, Australia, 2000

Key Executives

Name Title Year Born
Mr. Paul Edward-Alexander Hopper A.S.i.A, B.A (UNSW), FAICD Exec. Chairman 1956
Ms. Leslie Chong CEO, MD & Exec. Director NA
Dr. Nicholas J. Ede B.Sc.(Hons.), Ph.D. Chief Technology Officer NA
Dr. Monil Shah M.B.A., Pharm.D. Chief Bus. Officer NA
Mr. Michael Tonroe ACA, B.Sc., Bsc(Hons), F.C.A., M.A.I.C.D., MAICD Chief Financial Officer 1966
Ms. Ursula McCurry Sr. VP of Clinical Operations NA
Dr. Giovanni Selvaggi Chief Medical Officer NA
Mr. Nathan Jong C.A. Joint Company Sec. NA
Mr. Paul Edward-Alexander Hopper A.S.i.A, B.A (UNSW), FAICD Executive Chairman 1956
Mr. Paul Edward-Alexander Hopper A.S.i.A, B.A (UNSW), FAICD Executive Chairman 1956

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.